Lead Programme
Potent, resilient, once-yearly protection against influenza A
RQ Bio are delivering long-acting monoclonal antibodies (LAABs) that are uniquely designed to deliver potency and maintain resilience against the seasonal variation of influenza.
Potent and resilient LAABs targeting seasonal influenza A:
- Annual injection prophylactic to prevent serious disease in vulnerable individuals
- Designed to maximise potency while maintaining resilience to strain evolution
Where vaccines underperform, risk rises
- Low vaccine efficacy in the elderly and immunocompromised
- Immunocompromised individuals have an elevated risk of severe outcomes from flu infection
- Average VE between 2005 – 2024 from https://www.cdc.gov/flu-vaccines-work/php/effectiveness-studies/past-seasons-estimates.html
- Hughes, K. et al. Clin. Infect. Dis. 2021
Conserved target, blocked entry: LAABs built for potency & resilience
RQ Bio LAABs:
- Designed to target the invariant regions of a viral protein
- Achieve high potency due to blocking virus entry into host cell
- Maintain resilience to seasonal variation due to conserved nature of immune sub-dominant binding residues